key: cord-0812507-4j7ukl4o
authors: Farkhad, Najmeh Kaffash; Reihani, Hamidreza; sedaghat, Alireza; Moghadam, Amir Adhami; Moghadam, Ahmad Bagheri; Tavakol-Afshari, Jalil
title: Are Mesenchymal Stem Cells able to manage Cytokine Storm in COVID-19 patients? A review of recent studies
date: 2021-06-08
journal: Regen Ther
DOI: 10.1016/j.reth.2021.05.007
sha: c4dd9865a0e552cca0395d9de1cc44cdabdfd0c0
doc_id: 812507
cord_uid: 4j7ukl4o

The Covid-19 disease has recently become one of the biggest challenges globally, and there is still no specific medication. Findings showed the immune system in severe Covid-19 patients loses regulatory control of pro-inflammatory cytokines, especially IL-6 production, called the "Cytokine storm" process. This process can cause injury to vital organs, including lungs, kidneys, liver, and ultimately death if not inhibited. While many treatments have been proposed to reduce cytokine storm, but the safety and effectiveness of each of them are still in doubt. Mesenchymal stem cells (MSCs) are multipotent cells with self-renewal potential capable of suppressing overactive immune responses and leading to tissue restoration and repair. These immuno-modulatory properties of MSCs and their derivatives (like exosomes) can improve the condition of Covid-19 patients with serious infectious symptoms caused by adaptive immune system dysfunction. Many clinical trials have been conducted in this field using various MSCs around the world. Some of these have been published and summarized in the present article, while many have not yet been completed. Based on these available data, MSCs can reduce inflammatory cytokines, increase oxygen saturation, regenerate lung tissue and improve clinical symptoms in Covid-19 patients. The review article aims to collect available clinical data in more detail and investigate the role of MSCs in reducing cytokine storms as well as improving clinical parameters of Covid-19 patients for use in future clinical studies.

The Covid-19 is the biggest challenge in the medical world in the first half of the twenty-first century, and all scientists around the world are trying to find a way to tackle this problem.

The prevalence of new coronavirus (SARS-CoV-2) causing lung infection disease (3) . Covid-19 has a wide range of clinical symptoms, including cough, fever, lymphopenia, sore throat, fatigue, headache, and sense of taste or smells' loss (4) . One of the well-known facts about SARS-CoV-2 infection is its multi-organ downfall and Acute Respiratory Distress Syndrome (ARDS) in critical patients (5). This infection is correlated with a destructive inflammatory response, including releasing many pro-inflammatory cytokines called "Cytokine storm.". There is much evidence from the cytokine profile of Covid-19 patients, indicating that cytokine storm is directly linked to lung injury, multi-organ failure, and the disease's severity (6) (7) (8) .

So far, many treatment strategies for this disease have been proposed (9) (10) (11) , including hydroxychloroquine and combinations (11) (12) (13) , neutralizing antibodies (14) , repurposing various antiviral treatments (9, (15) (16) (17) , and passive antibody transfer from convalescent patients' sera (18, 19) . There are still controversies about these treatments, and they have a complementary role; besides, they seem insufficient due to the rapid progression of the J o u r n a l P r e -p r o o f disease and the increase in the number of patients, and certain limitations of any treatment method. For example, using high doses of steroids is not only useful in treating patients but can also cause severe side effects like the increased risk of bacterial infections or diabetes (20) (21) (22) . On the other hand, considering differences in the severity of the disease and individual discrepancies in the incidence of immune responses to some existing treatments, the need to find new treatment strategies is felt. In addition to inhibiting virus replication, perhaps one of the strategies to improve critically Covid-19 patients with severe lung involvement is to prevent cytokine storms formation.

Mesenchymal Stem Cells ( MSCs) and their derivatives may be able to prevent or mitigate this cytokine storm through their immunomodulatory capacity (23) and lack of expression of ACE2. Many clinical trials have been registered in line with MSCs therapy for Covid-19 patients (https://clinicaltrials.gov), many of which are still in the process, and only a few results have been published. Many review articles have also pointed to registered trials (24) (25) (26) (27) , but the article that summarizes the published results is not yet available. This review paper aims to investigate the role of MSCs in reducing and managing cytokine storms in Covid-19 patients based on summarizing the available results from recent studies that can provide useful information for clinicians and researchers in this field.

Cytokine storm is an inflammatory phenomenon which is marked by the systemic release of large numbers of cytokines including: Interleukin-6 (IL-6) , Interferon-gamma (IFNγ), Tumor Necrosis Factor-alpha (TNFα) , Interferon-alpha (IFNα ),Monocyte Chemoattractant Protein-1 (MCP-1) , Interleukin-1β (IL-1β) , Interferon-Beta (IFNβ ) , and Interleukin-2 (IL-2). The release of a large number of free radicals from immune cells is induced by these cytokines, which are the primary cause of Acute Respiratory Distress Syndrome (ARDS) and multiple organ failure (28) .

It has been proven that the internalization of the virus in tissue and immune cells leads to activation of the nuclear factor-kappa B (NF-kB) pathway and secretion of a myriad of inflammatory factors leading to Cytokine storm (29) . Indeed, a complex set of interactions between cytokines, cell types, and signaling pathways are involved in cytokine storm formation. The most important cells of the innate immune system involved in cytokine storms' pathogenesis are neutrophils, macrophages, and Natural killer cells (NK). Also, some T-lymphocyte subsets are involved in the cytokine storm process among adaptive immune system cells, including T-helper 1 (TH1), Cytotoxic T Lymphocyte (CTL) , and T-helper 17 (TH17) . T regulatory cell (Treg) discharge leads to an intensification in the levels of IFN-γ , IL-17 , and IL-6, and through the secretion of IL-8, decreases the neutrophils' clearance (30) .

Taking together all these observations is responsible for lung damage in Covid-19 and ARDS (31) . B cells are rarely contributed to the cytokine storm pathogenesis (32). Since cytokine storm is the main reason for morbidity in patients infected with SARS-CoV and MERS-CoV, recognizing it is vital in diagnosing and treating the disease by physicians. The medicinal problems of patients involved with cytokine storm can progress rapidly and have consequences such as hypoxemia, hemorrhages, anemia, thrombocytopenia, dyspnea, hypotension, vasodilatory shock, and death (33) . Immunosuppression is crucial in the treatment of cytokine storm in Covid-19 patients, especially those with severe conditions. Blocking IL-6, IL-1 and TNFα may prevent or inhibit the disease (34) .

As immune-suppressive, steroids were widely used to treat SARS to ameliorate the intensity of inflammatory injuries (35). However, high doses of steroids were not sufficient for treating extreme pulmonary injury in SARS and Covid-19 patients (20, 21) . Instead, they may lead to destructive side effects, including an increased risk of diabetes, osteonecrosis, severe bacterial infections, and cardiovascular disease (22) , dramatically affecting the prognosis. So 

Interleukin-6 (IL-6), among all cytokines, is more suspected to be involved in the cytokine storm induced by a coronavirus. IL-6 is tightly linked to mediate various immunomodulatory and inflammatory pathways (36) . It is produced by approximately all stromal cells and competent immune cells, including macrophages, mast cells, T lymphocytes, dendritic cells (DC) , monocytes, B lymphocytes, as well as some other non-lymphocytic cells, such as glomerular mesangial cells, endothelial cells, tumor cells, keratinocytes, and fibroblasts (37) . IL-6 performs as an alarming intermediary for the announcement of the occurrence of some urgent occasion. IL-6 is produced in infectious damage and transmits an alerting sign to the entire body (38) . IL-6 is responsible for activating TH17 cells in the interaction between T cell-dendritic cell (39) . In Covid-19 patients, an increased percentage of activated TH17 cells may be due to increased production of IL-6 in response to the virus's entry into the immune system (40) . It is recognized that IL-6 and D-Dimer levels dramatically increase in severe Covid-19 patients, and so they can be good diagnostic predictors for finding the severity of the disease (41) .It has been proven that the viral nucleocapsid SARS-CoV N protein is responsible for the elevated IL-6 levels and lung injury in the severe stage of disease progression in SARS patients (42). Besides, laboratory tests have indicated that IL-6 boosts macrophage activation syndrome (MAS), triggering mass manufacture of pro-inflammatory cytokines and inducing fibroblasts and neutrophils migration into the alveolar epithelium.

This results in an enlarged deposition of fibrin and collagen, leading to harm to underlining lung tissue (43, 44) . As a dominant pro-inflammatory cytokine, Tumor Necrosis Factor-α (TNF-α) is applied pleiotropic impacts on distinct cell types and critically is involved in viral diseases associated with the pathogenesis of chronic inflammatory (45) . It is known to be released by activated monocytes and is cytotoxic to tumor cells (46) . It has been proven that TNF-α triggers macrophage-induced angiogenesis, which is a virtual event throughout inflammation, tumor growth, and wound repair (47) .

As another mechanism, it is accepted that TNF and other cytokines in the TNF-TNF receptor superfamily are potent inducers of NF-κB, leading to multiple expression pro-inflammatory genes (32). Since TNFα is one of the most critical hyaline-production inducer cytokines in alveolar lung cells and fibroblasts, its high un-controlled rate in Covid-19 patients can cause serious lung damage (48) . Also obtained data from several studies show that anti-TNF therapy reduces morbidity and mortality in Covid-19 patients (49, 50) .

The interferons (IFNs) are a set of cytokines secreted by cells over a specific situation like exposure to viruses, polypeptides, or double-stranded RNA and have crucial immunomodulatory, antiviral, antitumor, and anti-proliferative properties (51). In mammals, this system is the first protective barrier against viral infection. This system's design is such that even at the cost of increasing the death rate of virus-infected cells, prevents the spread of the virus in the body (52) . Type I IFNs (IFN-α/β), as an essential part of the intrinsic antiviral innate immune system, are the fastest and most effective antiviral response as soon as the virus enters the body. Viral infections, including SARS-CoV-2, can suppress the production of IFN types 1 and 3 but induce the production of IL-6 and TNF. IFN type 1 might remarkably reduce viral replication (53) . Current studies show that IFN disorder is an J o u r n a l P r e -p r o o f important marker to discover Covid-19 pathogenesis. Efficient IFN stimulation or prophylactic direction of IFNs at the early stage before severe Covid-19 may bring about an autonomous antiviral state, limit the virus infection, and inhibit Covid-19 progression (54)

The interleukin-1(IL-1) cytokine family is consists of 11 members. Some more important of them are: IL-1α, IL-1β, IL-1 receptor antagonist (IL-1Ra), IL-18 , and IL-33 (55) . During the cytokine storm, IL-1 β, IL-18, and IL-33 are the three most essential cytokines from this family (56) . IL-1 family members boost the activity of the innate immune system cells. They also have crucial roles in provoking and amplifying the performance of polarized T cells.

Regardless of some exceptions, as a general rule, IL-18 mainly affects T helper 1 (TH1) cells, IL-33 mainly affects TH2 cells, and IL-1 has a crucial role in TH17 cell differentiation and maintenance (55) .

The benefits or disadvantages of IL-1 depends on the dosage. Although low doses may be protective, when it is generated in high doses in infectious diseases, it can be destructive; therefore, blocking it is necessary. When activating by SARS-CoV-2, IL-1 provokes the release of IL-6 and TNF-α , pro-inflammatory network that can cause cytokine storms and be detrimental both in the lung and systemically (57) .

Mesenchymal stem cells (MSCs) have been used in laboratory and clinical cell therapies for many years. MSCs are adult multipotent cells with self-renewal potential and multi-lineage differentiation ability into specialized cells (58). The long-term culture proficiency, easy accessibility, and control of how such cells specialize in forming the body's different tissues offer significant healthcare advances (59) .MSCs are accessible using simple methods and J o u r n a l P r e -p r o o f have been isolated from multiple tissues such as bone marrow (60) 

As mentioned, in Covid-19 patients, in a positive feedback of the immune system, it produces many inflammatory factors that lead to cytokine storms, and again the resulting cytokine storm causes overproduction of inflammatory cytokines and immune cells (73) .

disease-causing by various events, including the renin-angiotensin system dysregulation, cytokine storm, over-activation of neutrophils, and elevated coagulation (74) . The ARDS usually involves a general lung injury that is associated with characteristics such as J o u r n a l P r e -p r o o f pulmonary edema and damage to the endothelium of the lungs (75) . Unfortunately, the mortality rate caused by the 2019 coronavirus, leading to the induction of this severe lung damage (ARDS), is relatively high (76) . For example, in Huang et al. report, among critically covid-19 patients, 67-85% of them had ARDS, which is one of the leading causes of high mortality rates (61.5%) (4) . Many studies showed that MSCs are also useful in the treatment of ARDS (77, 78) .

MSCs therapy can theoretically suppress the overactive immune system, and by improving the microenvironment, assist endogenous restoration. After intravenously reaching the body, some of the MSCs accumulate in the lung and potentially prevent pulmonary fibrosis, protect lung pneumocytes, improve pulmonary microenvironment and enhance lung function (70, 76) . MSCs with raising autophagy through the phosphoinositol 3-kinase/protein B pathway may also defend alveolar cells (79) . Furthermore, it has been revealed that MSCs can secret some soluble bioactive factors and interact with damaged tissue leading to an increase in the population of T-regulatory cells and inhibit of Th1 and Th17 proliferation.

Besides, because of ATP levels reduction in injured alveolar epithelial cells, as another mechanism, MSCs by transporting mitochondria to these locations and refilling depleted ATPs, improve their functional status (72) . Also, in another mechanism, MSCs cause re-modeling and shift the T-cell subsets to tregulatory cells and subsequently, they increase the level of anti-inflammatory cytokine IL-10, which plays a crucial role in regulating immune responses.

To make these mechanisms of action more comfortable to understand, we have summarized the results from available studies in Fig.1 . Interestingly, using an RNA seq survey to identify 12,500 transplanted MSC in this study, the results showed that mesenchymal stem cells were ACE2 negative during treatment (76) .

Results reported in a different study by Lanzoni It has also been found that SARS-CoV-2 can affect liver cells by causing elevated levels of aminotransferase enzymes and liver impairment (106 Oxygen Species (ROS) and improve liver injury (113) . The results in the above studies (91, 94, 98) also showed a decrease in the number of liver enzymes after MSCs injection, resulting from the anti-inflammatory and immunomodulatory properties of these cells.

Besides , several studies have described renal involvement mainly due to Acute Kidney Injury (AKI ), affecting up to 70% of Covid-19 patients (114, 115) . The kidney is the second most affected organ in this disease, behind the lung and followed by the heart and the liver (116 

Combating COVID-19 with Mesenchymal Stem Cell therapy

Distinct stem/progenitor cells proliferate to regenerate the trachea

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet

Stem Cell Based Therapy Option in COVID-19: Is It Really Promising? Aging and disease

Potential treatments for COVID-19 related cytokine stormbeyond corticosteroids

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive care medicine

Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center's observational study

Di Napoli R. Features, evaluation and treatment coronavirus (COVID-19)

Potential antiviral therapeutics for

Zhonghua jie he he hu xi za zhi= Zhonghua jiehe he huxi zazhi= Chinese journal of tuberculosis and respiratory diseases

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Multicenter Collaboration Group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for

Chloroquine Phosphate for the Treatment of Novel Coronavirus Pneumonia

Structural insights into coronavirus entry

Antiviral therapy targeting viral polymerase. Current pharmaceutical design

Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection

Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China

Convalescent plasma: new evidence for an old therapeutic tool? Blood Transfusion

Passive immunotherapy: assessment of convalescent serum against Ebola virus Makona infection in nonhuman primates

Clinical findings, treatment and prognosis in patients with severe acute respiratory syndrome (SARS)

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. The Lancet

Steroid-Associated Side Effects

Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19. Frontiers of medicine

Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19

Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: gleaning insights for possible use in COVID-19. Stem cells translational medicine

The use of mesenchymal stromal cells in the treatment of coronavirus disease 2019

Into the eye of the cytokine storm

The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-an update on the status

Regulatory T cells and acute lung injury: cytokines, uncontrolled inflammation, and therapeutic implications

Restoring self-tolerance in autoimmune diseases by enhancing regulatory T-cells

Cytokine storm

Current concepts in the diagnosis and management of cytokine release syndrome

COVID-19 infection: the perspectives on immune responses

Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area

Evolutionary divergence and functions of the human interleukin (IL) gene family

Interleukin-6 and its receptor: from bench to bedside

Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis

IL-6: regulator of Treg/Th17 balance

The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality

Associations between immune-suppressive and stimulating drugs and novel COVID-19

Nucleocapsid protein of SARS-CoV activates interleukin-6 expression through cellular transcription factor NF-κB

The cytokine storm of COVID-19: a spotlight on prevention and protection

The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease

Anti-TNFα therapy of rheumatoid arthritis: what have we learned? Annual review of immunology

Tumor necrosis factor-α

Macrophage-induced angiogenesis is mediated by tumour necrosis factor-α

COVID-19: consider cytokine storm syndromes and immunosuppression. The lancet

Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study

Characteristics and prognosis of patients with inflammatory bowel disease during the SARS-CoV-2 pandemic in the Basque Country (Spain)

Interferons and their actions. Annual review of biochemistry

Viruses and interferons

Imbalanced host response to SARS-CoV-2 drives development of COVID-19

Dysregulated Interferon Response Underlying Severe COVID-19

The IL-1 family: regulators of immunity

The pathogenesis and treatment of theCytokine Storm'in COVID-19

2020;34. 58. Farkhad NK, Mahmoudi A, Mahdipour E. How Similar Are Human Mesenchymal Stem Cells Derived From Different Origins? A Review of Comparative Studies

Stem Cell Therapy: the ethical issues

Comparative study of the

Characteristics and immunomodulating functions of adipose-derived and bone marrowderived mesenchymal stem cells across defined human leukocyte antigen barriers

Comparison of mesenchymal stem cells derived from arterial, venous, and Wharton's jelly explants of human umbilical cord

Comparative analysis of human mesenchymal stem cells from umbilical cord, dental pulp, and menstrual blood as sources for cell therapy

Women's Attitudes, Willingness, and Barriers to Donation of Menstrual Blood

Differentiation of human mesenchymal stem cells (MSC) to dopaminergic neurons: A comparison between Wharton's Jelly and olfactory mucosa as sources of MSCs

Comparative evaluation of the isolation and quantification of stem cells derived from dental pulp and periodontal ligament of a permanent tooth and to assess their viability and proliferation on a platelet-rich fibrin scaffold

Mesenchymal stem cells and inflammatory lung diseases

Bone marrow concentrate (BMC) therapy in musculoskeletal disorders

Evidence-based policy position statement of American Society of Interventional Pain Physicians (ASIPP)

Expanded umbilical cord mesenchymal stem cells (UC-MSCs) as a therapeutic strategy in managing critically ill COVID-19 patients: the case for compassionate use

Mitochondrial transfer from MSCs to T cells induces Treg differentiation and restricts inflammatory response

Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury

Correspondence COVID-19: consider cytokine storm syndromes and

SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the'culprit lesion'of ARDS onset? What is there besides Tocilizumab? SGP130Fc

Diffuse alveolar damage associated mortality in selected acute respiratory distress syndrome patients with open lung biopsy

Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia

START study): a randomised phase 2a safety trial. The Lancet Respiratory Medicine

Therapeutic Implications of Human Umbilical Cord Mesenchymal Stromal Cells in Attenuating Influenza A (H5N1) Virus-Associated Acute Lung Injury. The Journal of infectious diseases

Bone marrow-derived mesenchymal stem cells enhance autophagy via PI 3K/AKT signalling to reduce the severity of ischaemia/reperfusion-induced lung injury

Mesenchymal stem cells in the fight against viruses: face to face with the invisible enemy. Current Research in Translational Medicine

New concepts on the immune modulation mediated by mesenchymal stem cells

Mesenchymal stem cells: a doubleedged sword in regulating immune responses

Multipotent mesenchymal stromal cells and the innate immune system

Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells

Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells

Mesenchymal stem cell therapy for the treatment of inflammatory diseases: challenges, opportunities, and future perspectives

Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications

Stem cell therapy for COVID-19, ARDS and pulmonary fibrosis

Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: A case report

Umbilical cord-derived mesenchymal stem cells for COVID-19 patients with acute respiratory distress syndrome (ARDS)

Intravenous infusion of human umbilical cord Wharton's jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia

Effect of human umbilical cordderived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial. Signal transduction and targeted therapy

Umbilical cord blood-derived mesenchymal stem cells in treating a critically ill COVID-19 patient

Systemic administration of human umbilical cord-derived mesenchymal stem cells effectively ameliorates the outcomes of a critically ill elderly patient with COVID-19 with multiple comorbidities: A case report

Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19. Frontiers of medicine

Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series

Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study

Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial. Signal transduction and targeted therapy

Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19

Mesenchymal stem cell therapy in severe COVID-19: A retrospective study of short-term treatment efficacy and side effects

Treatment of severe COVID

Laboratory abnormalities in patients with

Innate immune recognition. Annual review of immunology

Comparison of pre-and postlevothyroxine high-sensitivity c-reactive protein and fetuin-a levels in subclinical hypothyroidism

A comprehensive appraisal of laboratory biochemistry tests as major predictors of COVID-19 severity. Archives of pathology & laboratory medicine

SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases

Clinical characteristics of patients with 2019 coronavirus disease in a non-Wuhan area of Hubei Province, China: a retrospective study

Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. The Lancet Infectious Diseases

Clinical characteristics of coronavirus disease 2019 in China

Liver injury in COVID-19: management and challenges

Evaluation of Hepatic Enzymes Changes and Association with Prognosis in COVID-19 Patients

Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19

Mesenchymal stem cells restore

CCl4-induced liver injury by an antioxidative process

Acute kidney injury in the 2019 novel coronavirus disease. Kidney diseases

Acute kidney injury in coronavirus disease 2019 infected patients: a meta-analytic study

Retrospective analysis of laboratory testing in 54 patients with severe-or critical-type 2019 novel coronavirus pneumonia

Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney international

Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury

Multipotent mesenchymal stem cells reduce interstitial fibrosis but do not delay progression

Cytokine storm intervention in the early stages of COVID-19 pneumonia